Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
This study has been completed.
AbbVie (prior sponsor, Abbott)
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) )
First received: August 16, 2007
Last updated: March 29, 2013
Last verified: January 2013
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||June 2012|
|Primary Completion Date:||June 2011 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||July 13, 2012|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Tan EH, Goss GD, Salgia R, Besse B, Gandara DR, Hanna NH, Yang JC, Thertulien R, Wertheim M, Mazieres J, Hensing T, Lee C, Gupta N, Pradhan R, Qian J, Qin Q, Scappaticci FA, Ricker JL, Carlson DM, Soo RA. Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011 Aug;6(8):1418-25. doi: 10.1097/JTO.0b013e318220c93e.